SCHEMBL7141933

SCHEMBL7141933

CCOC(=O)C1=CC=CC=CN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.42
CA2 P00918 5/20 0.42
CA12 O43570 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA14 Q9ULX7 4/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
CYP1A2 P05177 3/20 0.41
LMNA P02545 3/20 0.41
CYP3A4 P08684 1/20 0.41
MAOA P21397 1/20 0.41
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 2/20 0.38
RECQL P46063 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27772092 0.98 CA1 (0.41) CA1CA2CA12CA7CA9
SCHEMBL18053020 0.79 CA12 (0.40) CA1CA2CA12CA7CA9
SCHEMBL27694354 0.79 CA12 (0.30) CA1CA2CA12CA9
SCHEMBL28522456 0.76 TSHR (0.38) CA1CA2CA12CA7CA9
SCHEMBL28325349 0.76 MAPT (0.33) CYP3A4MEN1KMT2AMAPTL3MBTL1
SCHEMBL6193368 0.75 CA12 (0.34) CA1CA2CA12CA9CA14
SCHEMBL7372019 0.74 SMN1; SMN2 (0.41) CA1CA2CA12CA9LMNA
SCHEMBL5282811 0.73 CA1 (0.43) CA1CA2CA12CA7CA9
SCHEMBL28015333 0.72 CA5A (0.30)
SCHEMBL27387808 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112204036-B Macrocyclic fused pyrazoles as MCL-1 inhibitors 苏州亚盛药业有限公司 2022-12-27 CN disclosed
CN-114828894-A Polymer-supported thienoazepine compounds and uses thereof 博尔特生物治疗药物有限公司 2022-07-29 CN disclosed
CN-112204036-A Macrocyclic fused pyrazoles as MCL-1 inhibitors 苏州亚盛药业有限公司 2021-01-08 CN disclosed
EP-2649077-A1 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2013-10-16 EP disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed
US-6512112-B2 Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria PHARMACIA & UPJOHN COMPANY 2003-01-28 US disclosed
US-20010051722-A1 Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria GADWOOD ROBERT C (US) 2001-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051722-A1 Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria AMD1, CYP11B1, ALDH7A1 CA1 2946/4885CA2 2697/4885CA12 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.